

1FW



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q93343

Hiroyuki NAKAHIRA, et al.

Appln. No.: 10/595,125

Group Art Unit: Unknown

Confirmation No.: 3047

Examiner: Unknown

Filed: August 25, 2004

For: BICYCLIC PYRAZOLE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents except US Patents and Patent Publications is submitted herewith.

1. U.S. Patent Publication No. 2002-198205 A1, published December 26, 2002 to Himmelsbache et al.
2. U.S. Patent Publication No. 2004-077645 A1, published April 22, 2004 to Himmelsbach et al.
3. U.S. Patent Publication No. 2004-0087587 A1, published May 6, 2004 to Himmelsbach et al.

Hiroyuki NAKAHIRA et al.
INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/595,125
April 28, 2006

References 1-3 above correspond to WO 02/068420 A1, which was cited in the International Search Report and was previously listed on a PTO/SB/08 A & B.

4. U.S. Patent Publication No. 2002-0169174 A1, published November 14, 2002 to Chackalamannil et al.
5. U.S. Patent Publication No. 2004-0167137 A1, published August 26, 2004 to Chackalamannil et al.
6. U.S. Patent Publication No. 2004-0229885 A1, published November 18, 2004 to Chackalamannil et al.
7. U.S. Patent Publication No. 2005-0075349 A1, published April 7, 2005 to Chackalamannil et al.
8. U.S. Patent No. 6,821,978, issued November 13, 2004 to Chackalamannil et al.

References 4-8 above correspond to WO 02/24698 A1, which was cited in the International Search Report and was previously listed on a PTO/SB/08 A & B.

9. U.S. Patent Publication No. 2004-082570 A1, published April 29, 2004 to Yoshikawa et al.

Reference 9 above corresponds to JP 2004-43429 A, which was cited in the International Search Report and was previously listed on a PTO/SB/08 A & B.

10. WO 02/02560 A2, published January 10, 2002 to Novo Nordisk A/S.
11. U.S. Patent Publication No. 2002-0161001 A1, published October 31, 2002 to Kanstrup et al. This reference corresponds to WO 02/02560, listed above.
12. U.S. Patent Publication No. 2004-0034014 A1, published February 19, 2004 to Kanstrup et al. This reference corresponds to WO 02/02560, listed above.
13. WO 03/004496 A1, published January 16, 2003 to Novo Nordisk A/S.
14. U.S. Patent Publication No. 2003/0105077 A1, published June 5, 2003 to Kanstrup et al. This reference corresponds to WO 03/004496, listed above.
15. U.S. Patent Publication No. 2005/0148606 A1, published July 7, 2005 to Kanstrup et al. This reference corresponds to WO 03/004496, listed above.

Hiroyuki NAKAHIRA et al.
INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/595,125
April 28, 2006

16. WO 03/024965 A2, published March 27, 2003 to Novo Nordisk A/S.
17. U.S. Patent Publication No. 2003/0199528 A1, published October 23, 2003 to Kanstrup et al. This reference corresponds to WO 03/024965, listed above.
18. L.B. Kundsén et al., "Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1 (7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor", European Journal of Pharmacology, Vol. 318, (1996), pp. 429-435.
19. T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV", Endocrinology, Vol. 136, No. 8, (1995), pp. 3585-3596.
20. R.A. Pederson et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide", Diabetes, Vol. 47, (1998), pp. 1253-1258.
21. Cellular Peptidases In Immune Functions and Diseases 2, edited by Langner and Ansorge, Kluwer Academic/Plenum Publishers, (2000), pp. 111-122, 336-338 and 522.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not

Hiroyuki NAKAHIRA et al.
INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/595,125
April 28, 2006

waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER


John T. Callahan
Registration No. 32,607

Date: April 28, 2006

Substitute for Form 1449 A & B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/595,125
Confirmation Number	3047
Filing Date	February 27, 2006
First Named Inventor	Hiroyuki NAKAHIRA
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q93343

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 2002/0198205	A1	12/26/2002	Himmelsbach et al.
		US 2004/0077645	A1	04/22/2004	Himmelsbach et al.
		US 2004/0087587	A1	05/06/2004	Himmelsbach et al.
		US 2002/0169174	A1	11/14/2002	Chackalamannil et al.
		US 2004/0167137	A1	08/26/2004	Chackalamannil et al.
		US 2004/0229885	A1	11/18/2004	Chackalamannil et al.
		US 2005/0075349	A1	04/07/2005	Chackalamannil et al.
		US 6,821,978	B2	11/23/2004	Chackalamannil et al.
		US 2004/0082570	A1	04/29/2004	Yoshikawa et al.
		US 2002/0161001	A1	10/31/2002	Kanstrup et al.
		US 2004/0034014	A1	02/19/2004	Kanstrup et al.
		US 2003/0105077	A1	06/05/2003	Kanstrup et al.
		US 2005/0148606	A1	07/07/2005	Kanstrup et al.
		US 2003/0199528	A1	10/23/2003	Kanstrup et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	02/02560	A2	01/10/2002	Novo Nordisk A/S	
		WO	03/004496	A1	01/16/2003	Novo Nordisk A/S	
		WO	03/024965	A2	03/27/2003	Novo Nordisk A/S	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		L.B. Kundsén et al., "Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1 (7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor", European Journal of Pharmacology, Vol. 318, (1996), pp. 429-435.	
		T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 in Vitro and in Vivo by Dipeptidyl Peptidase IV", Endocrinology, Vol. 136, No. 8, (1995), pp. 3585-3596.	
		R.A. Pederson et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide", Diabetes, Vol. 47, (1998), pp. 1253-1258.	
		Cellular Peptidases In Immune Functions and Diseases 2, edited by Langner and Ansorge, Kluwer Academic/Plenum Publishers, (2000), pp. 111-122, 336-338 and 522.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.